COCRYSTALLINE DHEA FORMULATIONS

Research output: Patent

Anders L. Berkenstam (Inventor), Edward Kuczynski, (Inventor), S Andersson, Alf (Inventor), Jan-Ake Gustafsson, (Inventor), Carly S. Filgueira (Inventor)

A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

Original languageEnglish (US)
Patent numberWO2014172706
IPCA61K 38/ 22 A I
Priority date4/19/13
StatePublished - Oct 23 2014

Cite this

Standard

COCRYSTALLINE DHEA FORMULATIONS. / Berkenstam, Anders L. (Inventor); Kuczynski, Edward (Inventor); Andersson, Alf, S (Inventor); Gustafsson, Jan-Ake (Inventor); Filgueira, Carly S. (Inventor).

IPC No.: A61K 38/ 22 A I. Patent No.: WO2014172706.

Research output: Patent

Harvard

Berkenstam, AL, Kuczynski, E, Andersson, Alf, S, Gustafsson, J-A & Filgueira, CS 2014, COCRYSTALLINE DHEA FORMULATIONS, Patent No. WO2014172706, IPC No. A61K 38/ 22 A I.

APA

Berkenstam, A. L., Kuczynski, E., Andersson, Alf, S., Gustafsson, J-A., & Filgueira, C. S. (2014). IPC No. A61K 38/ 22 A I. COCRYSTALLINE DHEA FORMULATIONS. (Patent No. WO2014172706).

Vancouver

Berkenstam AL, Kuczynski, E, Andersson, Alf S, Gustafsson, J-A, Filgueira CS, inventors. COCRYSTALLINE DHEA FORMULATIONS. A61K 38/ 22 A I. 2014 Oct 23.

Author

Berkenstam, Anders L. (Inventor) ; Kuczynski, Edward (Inventor) ; Andersson, Alf, S (Inventor) ; Gustafsson, Jan-Ake (Inventor) ; Filgueira, Carly S. (Inventor). / COCRYSTALLINE DHEA FORMULATIONS. IPC No.: A61K 38/ 22 A I. Patent No.: WO2014172706.

BibTeX

@misc{32c55ad531df4e96b178091db42cb358,
title = "COCRYSTALLINE DHEA FORMULATIONS",
abstract = "A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.",
author = "Berkenstam, {Anders L.} and Edward Kuczynski, and {Andersson, Alf}, S and Jan-Ake Gustafsson, and Filgueira, {Carly S.}",
year = "2014",
month = "10",
day = "23",
language = "English (US)",
type = "Patent",
note = "WO2014172706; A61K 38/ 22 A I",

}

RIS

TY - PAT

T1 - COCRYSTALLINE DHEA FORMULATIONS

AU - Berkenstam, Anders L.

AU - Kuczynski,, Edward

AU - Andersson, Alf, S

AU - Gustafsson,, Jan-Ake

AU - Filgueira, Carly S.

PY - 2014/10/23

Y1 - 2014/10/23

N2 - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

AB - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

M3 - Patent

M1 - WO2014172706

ER -

Similar Research Outputs

  1. Cocrystalline DHEA Formulations

    Berkenstam, A. L., Kuczynski, E., Andersson, Alf, S., Gustafsson, J-A. & Filgueira, C. S., Oct 23 2014, IPC No. C07C 49/ 727 A I, Patent No. US2014315833, Priority date Apr 21 2014, Priority No. US201414257594

    Research output: Patent

ID: 32366074